


Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Box Non-Fee Amendment**, Commissioner for Patents, Washington, D.C. 20231 on November 14, 2002.

By: 

Printed: Margaret M. Hasson

# = / N.T.  
11/20  
E.E.E. 11/20/02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re. Application of: Walker et al.

Title: DIAGNOSTICS AND THERAPEUTICS FOR PANCREATIC DISORDERS

Serial No.: 09/864,711

Filing Date: May 23, 2001

Examiner: Martinell, J

Group Art Unit: 1631

**Box Non-Fee Amendment**

Commissioner for Patents

Washington, D.C. 20231

RECEIVED  
NOV 22 2002  
TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121**

Sir:

This paper is responsive to the Restriction Requirement and Request for Election dated October 22, 2002, setting a one (1) month term for response.

**Restriction Requirement**

In the Restriction Requirement, the Examiner requested Applicants to elect one of the following inventions:

Group I (claim 1) drawn to a combination of polynucleotides.

Group II (claims 2, 3 and 13-15) drawn to polynucleotides, vectors, host cells, and methods of making polypeptides.

Group III (claims 4-12) drawn to nucleotide binding assays.

Group IV (claims 16 and 17) drawn to proteins and compositions containing proteins.

Group V (claims 18-20) drawn to protein binding assays.

The Examiner stated that if Group I is chosen, the combination will be searched until one nucleotide sequence is found allowable.

The Examiner stated that if Groups II or III are chosen, the claims are subject to restriction under 35 U.S.C. § 121 as outlined in 1192 O.G. 68 (November 19, 1996) which permits the examination of from one to ten independent and distinct nucleotide sequences in a single application based upon USPTO resources. The Examiner therefore required Applicant to choose no more than one selected sequences which may include the complements of the selected sequences and, where appropriate, may include subsequences within the selected sequences.

The Examiner stated that if Groups VI or V are chosen, applicants are required to select one polypeptide sequence for examination or merits.

Applicants hereby elect, with traverse, to prosecute Group I, which includes and is drawn to claim 1. Applicants submit that at the very least claims 2, 3 and 13-15 of Group II could be examined with respect to the allowable sequence identified in claim 1 without an additional burden of search. Applicants therefore request reconsideration of the Restriction Requirement and examination of claims 1-3 and 13-15 with respect to the allowable sequence found by the Examiner in the examination of SEQ ID NO:1-13 of claim 1. Applicants reserve the right to prosecute the subject matter of non-elected claims in subsequent divisional applications.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 09-0108.

Respectfully submitted,  
 INCYTE GENOMICS, INC.

Date: November 14, 2002 David G. Streeter  
 David G. Streeter, Ph.D.  
 Reg. No. 43,168  
 Direct Dial Telephone: (650) 845-5741

3160 Porter Drive  
 Palo Alto, California 94304  
 Phone: (650) 855-0555  
 Fax: (650) 849-8886